#USA #San Diego #Primrose Bio #RNA Polymerase #mRNA Production

Primrose Bio Launches Two Innovative RNA Polymerases

Primrose Bio, Inc., a pioneering provider of production solutions for next-generation biologics, has recently unveiled two advanced RNA polymerases designed to improve the quality and cost-effectiveness of mRNA. This launch marks a significant step in mRNA technology, directly addressing the pressing needs of drug developers by enhancing RNA synthesis processes.

The Innovations Behind the Products

The two new products are: Prima RNApols® Cap AG and Prima RNApols® 7 Pro. Both are engineered to deliver high-quality RNA more economically than existing solutions. Their capabilities include:

• - Prima RNApols® Cap AG: This enzyme is optimized for workflows that require AG-capping. It has demonstrated production of RNA with up to three times better protein expression, while achieving over 97% capping efficiency. Impressively, it uses less than half the cap analog per reaction compared to previous models, presenting a more efficient alternative for researchers focused on quality and output.
• - Prima RNApols® 7 Pro: This versatile polymerase has been enhanced for better protein expression and capping efficiency while remaining compatible with the T7 promoter sequence. It supports both AG and AU-capped mRNAs and aims to further streamline the RNA synthesis process.

RNA polymerases are key players in in vitro transcription (IVT), responsible for synthesizing RNA from DNA templates. The presence of double-stranded RNA (dsRNA) byproducts can trigger innate immune responses, leading to suppressed protein production. By effectively reducing these impurities, Primrose's new polymers can aid in producing therapeutic proteins or vaccine antigens with minimized unwanted immune activation.

Andrew Burch, CEO of Primrose Bio, emphasized the transformative impact of these new products: "This launch reflects years of enzyme engineering to deliver RNA polymerases that we believe offer substantial improvements over what is currently available to drug developers. Our goal is to make high-quality RNA easier and more economical to produce for the next generation of RNA medicines."

Upcoming Showcases

Primrose Bio will present its two new polymerases at two major events: the Alliance for mRNA Medicines' second annual meeting, AMM Ascent, from October 28-30 in Coronado, and the 14th International mRNA Health Conference, scheduled for November 17-19 in Boston. Attendees will have the opportunity to witness the advantages of these new products first-hand.

About Prima RNApols®

The Prima RNApols product line includes RNA polymerases meticulously designed to enhance RNA quality while also improving manufacturing economics across all RNA workflows. Their portfolio consists of specialized options tailored for different template designs, capping chemistries, and IVT conditions. These include:

• - Prima RNApols Cap AU: Optimized for AU-capped and longer-template mRNA.
• - Customized RNA Polymerase Services: Tailored solutions for specific manufacturing challenges, enhancing flexibility for developers.

Company Overview

Primrose Bio, Inc. has been at the forefront of manufacturing technology that bridges the gaps in biologics, mRNA, and vaccine production. Their offerings also include Pfenex Expression Technology, a proprietary microbial production system that has led to substantial yield increases in approved products. Furthermore, notable pharmaceutical companies such as Merck and Serum Institute of India utilize Primrose's technologies in their marketed products.

For more information regarding their new RNA polymerases, visit Primrose Bio's official website or explore their product page at Prima. For inquiries regarding GMP-grade Prima RNApols, interested parties can contact them via email.

In conclusion, with these newly launched RNA polymerases, Primrose Bio is poised to significantly impact the landscape of mRNA synthesis, paving the way for advancements in RNA-based therapeutics and vaccines.